Literature DB >> 28851699

An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Jonathan C Poe1, Wei Jia1, Hsuan Su1, Sarah Anand1, Jeremy J Rose2, Prasanthi V Tata3, Amy N Suthers1, Corbin D Jones4, Pei Fen Kuan5, Benjamin G Vincent3, Jonathan S Serody3, Mitchell E Horwitz1, Vincent T Ho6, Steven Z Pavletic2, Frances T Hakim2, Kouros Owzar7, Dadong Zhang7, Bruce R Blazar8,9, Christian W Siebel10, Nelson J Chao1, Ivan Maillard11,12, Stefanie Sarantopoulos1.   

Abstract

B-cell receptor (BCR)-activated B cells contribute to pathogenesis in chronic graft-versus-host disease (cGVHD), a condition manifested by both B-cell autoreactivity and immune deficiency. We hypothesized that constitutive BCR activation precluded functional B-cell maturation in cGVHD. To address this, we examined BCR-NOTCH2 synergy because NOTCH has been shown to increase BCR responsiveness in normal mouse B cells. We conducted ex vivo activation and signaling assays of 30 primary samples from hematopoietic stem cell transplantation patients with and without cGVHD. Consistent with a molecular link between pathways, we found that BCR-NOTCH activation significantly increased the proximal BCR adapter protein BLNK. BCR-NOTCH activation also enabled persistent NOTCH2 surface expression, suggesting a positive feedback loop. Specific NOTCH2 blockade eliminated NOTCH-BCR activation and significantly altered NOTCH downstream targets and B-cell maturation/effector molecules. Examination of the molecular underpinnings of this "NOTCH2-BCR axis" in cGVHD revealed imbalanced expression of the transcription factors IRF4 and IRF8, each critical to B-cell differentiation and fate. All-trans retinoic acid (ATRA) increased IRF4 expression, restored the IRF4-to-IRF8 ratio, abrogated BCR-NOTCH hyperactivation, and reduced NOTCH2 expression in cGVHD B cells without compromising viability. ATRA-treated cGVHD B cells had elevated TLR9 and PAX5, but not BLIMP1 (a gene-expression pattern associated with mature follicular B cells) and also attained increased cytosine guanine dinucleotide responsiveness. Together, we reveal a mechanistic link between NOTCH2 activation and robust BCR responses to otherwise suboptimal amounts of surrogate antigen. Our findings suggest that peripheral B cells in cGVHD patients can be pharmacologically directed from hyperactivation toward maturity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28851699      PMCID: PMC5680609          DOI: 10.1182/blood-2017-05-782466

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  68 in total

1.  Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8.

Authors:  Heping Xu; Virendra K Chaudhri; Zhiguo Wu; Konstantinos Biliouris; Krista Dienger-Stambaugh; Yrina Rochman; Harinder Singh
Journal:  Nat Immunol       Date:  2015-10-05       Impact factor: 25.606

2.  Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk.

Authors:  M Turner; P J Mee; P S Costello; O Williams; A A Price; L P Duddy; M T Furlong; R L Geahlen; V L Tybulewicz
Journal:  Nature       Date:  1995-11-16       Impact factor: 49.962

3.  A role for IRF8 in B cell anergy.

Authors:  Simanta Pathak; Shibin Ma; Vipul Shukla; Runqing Lu
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

Review 4.  Mechanistic approaches for the prevention and treatment of chronic GVHD.

Authors:  Corey S Cutler; John Koreth; Jerome Ritz
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

5.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

6.  Retinoids accelerate B lineage lymphoid differentiation.

Authors:  Xinrong Chen; Brandt L Esplin; Karla P Garrett; Robert S Welner; Carol F Webb; Paul W Kincade
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

7.  Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells.

Authors:  Kuo-I Lin; Cristina Angelin-Duclos; Tracy C Kuo; Kathryn Calame
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

8.  Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Corey S Cutler; Nazmim S Bhuiya; Michael Schowalter; Vincent T Ho; Edwin P Alyea; John Koreth; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

Review 9.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

10.  Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells.

Authors:  Giuliana Magri; Michio Miyajima; Sabrina Bascones; Arthur Mortha; Irene Puga; Linda Cassis; Carolina M Barra; Laura Comerma; Aleksey Chudnovskiy; Maurizio Gentile; David Llige; Montserrat Cols; Sergi Serrano; Juan Ignacio Aróstegui; Manel Juan; Jordi Yagüe; Miriam Merad; Sidonia Fagarasan; Andrea Cerutti
Journal:  Nat Immunol       Date:  2014-02-23       Impact factor: 25.606

View more
  16 in total

1.  [Structure and function of B-cell linker and its role in the development of B cell-related diseases].

Authors:  Bin Xiao; Jiaying Li; Mengsi Zhou; Xiaoqing Li; Xiaoyan Huang; Jianfeng Hang; Zhaohui Sun; Linhai Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

Review 2.  B-cell targeting in chronic graft-versus-host disease.

Authors:  Robert Zeiser; Stefanie Sarantopoulos; Bruce R Blazar
Journal:  Blood       Date:  2018-02-01       Impact factor: 22.113

3.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04

Review 4.  How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.

Authors:  Samantha M Jaglowski; Bruce R Blazar
Journal:  Blood Adv       Date:  2018-08-14

5.  BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation.

Authors:  Wei Jia; Jonathan C Poe; Hsuan Su; Sarah Anand; Glenn K Matsushima; Jeffrey C Rathmell; Ivan Maillard; Vedran Radojcic; Kazuhiro Imai; Nancy J Reyes; Diana M Cardona; Zhiguo Li; Amy N Suthers; Itaevia M Curry-Chisolm; Rachel A DiCioccio; Daniel R Saban; Benny J Chen; Nelson J Chao; Stefanie Sarantopoulos
Journal:  Blood       Date:  2021-05-06       Impact factor: 25.476

Review 6.  Developing role of B cells in the pathogenesis and treatment of chronic GVHD.

Authors:  Xiaoping Li; Qiangguo Gao; Yimei Feng; Xi Zhang
Journal:  Br J Haematol       Date:  2018-12-26       Impact factor: 6.998

7.  Lipocalin 10 as a New Prognostic Biomarker in Sepsis-Induced Myocardial Dysfunction and Mortality: A Pilot Study.

Authors:  Lu Wang; Wenjie Xie; Guang Li; Bo Hu; Wei Wu; Liying Zhan; Handong Zou
Journal:  Mediators Inflamm       Date:  2021-05-22       Impact factor: 4.711

8.  Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.

Authors:  Vedran Radojcic; Katelyn Paz; Jooho Chung; Jing Du; Eric T Perkey; Ryan Flynn; Sanja Ivcevic; Michael Zaiken; Ann Friedman; Minhong Yan; Maria A Pletneva; Stefanie Sarantopoulos; Christian W Siebel; Bruce R Blazar; Ivan Maillard
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476

Review 9.  Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.

Authors:  Leslie S Kean
Journal:  Blood       Date:  2018-05-04       Impact factor: 25.476

Review 10.  NOTCH and Graft-Versus-Host Disease.

Authors:  Mauro Di Ianni; Beatrice Del Papa; Stefano Baldoni; Ambra Di Tommaso; Bianca Fabi; Emanuela Rosati; Annalisa Natale; Stella Santarone; Paola Olioso; Gabriele Papalinetti; Raffaella Giancola; Patrizia Accorsi; Paolo Di Bartolomeo; Paolo Sportoletti; Franca Falzetti
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.